特发性血小板减少性紫癜(ITP)是一种自身免疫性疾病,系抗血小板抗体引起血小板破坏而导致严重的出血。常规的治疗是使用糖皮质激素、免疫抑制剂、抗人CD20单克隆抗体或脾切除,但这些疗法会引起复发或许多不良反应。最近的研究显示:血小板生成素是能调节血小板产生的细胞因子,罗米司亭是一种重组Fc肽融合蛋白,能增加慢性ITP患者的血小板数量。文中综述了其作用机制、药效学、药动学和临床评价。 Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease that causes severe bleeding due to platelet destruction caused by anti-platelet antibodies. Conventional treatment is the use of glucocorticoids, immunosuppressive agents, anti-human CD20 monoclonal antibodies or splenectomy, but these therapies can cause recurrence or many adverse reactions. Recent studies have shown that thrombopoietin is a cytokine that modulates platelet production and that lumiposit is a recombinant Fc-peptide fusion protein that increases the number of platelets in patients with chronic ITP. In this paper, the mechanism of action, pharmacodynamics, pharmacokinetics and clinical evaluation were reviewed.